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Abstract  
Objective: The literature on antiplatelet therapy for peripheral arterial disease has 
historically been summarised inconsistently, leading to conflict between international 
guidleines. An umbrella review and meta-analysis was performed to clearly 
summarise the literature, allow assessment of competing safety risks and clinical 
benefits, and identify weak areas for future research.  
Methods: MEDLINE, EMBASE, DARE, PROSPERO and Cochrane databases were 
searched from inception until January 2019.  All meta-analyses of antiplatelet 
therapy in peripheral arterial disease were included.  Quality was assessed using 
Amstar scores, with GRADE analysis quantifying strength of evidence.  Data were 
pooled using random-effects models. 
Results: Twenty-eight meta-analyses were included.  Thirty-three clinical outcomes 
and 41 antiplatelet comparisons in 72,181 patients were analysed. High-quality 
evidence showed antiplatelet monotherapy reduced non-fatal strokes and 
cardiovascular death in symptomatic patients (3 and 8 fewer per 1000 patients 
respectively, 95% CI 0–6 and 0–16), but increased risk of major bleeding (7 more 
per 1000, 95% CI 3–14). In asymptomatic patients, monotherapy reduced non-fatal 
strokes (5 fewer per 1000, 95% CI 0–8) but had no other clinical benefit. Dual 
antiplatelet therapy caused more major bleeding after intervention than monotherapy 
(37 more per 1000, 95% CI 8–102), with very low-quality evidence of improved 
endovascular patency (Relative Risk 4.00, 95% CI 0.91–17.68). 
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Conclusions: Antiplatelet monotherapy has minimal clinical benefit for 
asymptomatic peripheral arterial disease, and limited benefit for symptomatic 
disease, with clear risk of major bleeding. There is a lack of evidence to guide 
antiplatelet prescribing after peripheral endovascular intervention which needs 
addressing by adequately powered randomised trials. 
 
Study registration: PROSPERO 2017 CRD42017084223 
Key words: Antiplatelet therapy; Peripheral arterial disease; Systematic review; 
Meta-analysis   
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Introduction 
Peripheral arterial disease (PAD) affects over 200 million people worldwide and is 
predicted to increase with the global diabetes expansion.1,2 Guideline groups in the 
UK,3 USA4 and Europe5 recommend antiplatelet therapy for patients with PAD. 
However, the specific recommendations in these guidelines are inconsistent.  
The National Institute for health and Care Excellence (NICE)3 in the UK and the 
American College of Cardiology/ American Heart Association (ACC/AHA)4 in the 
USA recommend antiplatelet monotherapy for secondary prevention of 
cardiovascular events in all patients with PAD. The joint European Society for 
Vascular Surgery (ESVS) / European Society of Cardiology (ESC)5 guidelines 
restrict this to symptomatic PAD. Dual antiplatelet therapy after peripheral 
intervention “may be reasonable to use” in the ACC/AHA guidelines and is 
recommended after lower limb stenting and prosthetic bypass by the ESC. NICE do 
not make a recommendation. There is currently a trend towards prescribing dual 
antiplatelet therapy after endovascular lower limb intervention based mainly on the 
coronary stenting literature.6-8 There are problems with this practice; flow dynamics 
and patterns of atherosclerosis are different in the coronary and peripheral arteries, 
and the risks and benefits of dual antiplatelet therapy compared to monotherapy are 
far less clear in the PAD literature than the coronary literature.  
PAD antiplatelet guidelines conflict with one another because data were 
variably aggregated from heterogeneous trials of multiple antiplatelet regimes and 
agents, some of which were discontinued decades ago. The PAD populations in the 
trials were also a mixture of patients with claudication and critical ischaemia, who are 
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different both in terms of cardiovascular risk and the risk of thrombosis of the 
interventions.5,9  
Randomised trials in the peripheral arterial population are more relevant than 
ever for several reasons: Clopidogrel, which is recommended by guidelines is now 
off patent;3 several new antiplatelet agents and anticoagulants have become 
available and are being investigated in this population,10,11 and calls for trials of 
cheap commonly prescribed drugs in the peripheral arterial population are being 
published.12  
Patients with PAD are at high risk of cardiovascular events,13 so it is important 
that we clarify the best ways to optimize their management, but before high quality 
future trials can be designed, the literature must be systematically assessed so that 
the quality of data and strength of effect for all antiplatelet outcomes in PAD can be 
examined and compared. The best way to assimilate such a large amount of data is 
using umbrella review methodology.14 This is because while individual outcomes 
and/or antiplatelet agents have been meta-analysed extensively in the past, there 
has never been a critical comparison of all available outcomes.  
The aim of this study was to definitively assess the evidence from randomised 
trials of antiplatelet therapy in patients with PAD.  This will both facilitate the 
clarification of international guidelines and define the areas where further research is 
required.  
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Methods 
For this study, a systematic umbrella review of meta-analyses examining antiplatelet 
therapy for any outcome in patients with PAD was performed. This allows an in-
depth overview of a broad topic and facilitates comparisons between outcomes to 
examine the relative importance of each.14,15 It also highlights deficiencies in the 
literature. The study was registered on PROSPERO on 14th December 2017 
(PROSPERO 2017 CRD42017084223 Available from: 
http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD4201708422
3). As there are no internationally accepted guidelines for reporting umbrella reviews, 
both PRISMA,16 and the most recent framework evaluation for reporting of overviews 
of systematic reviews (umbrella reviews)15 were followed.  
 
Literature search 
MEDLINE and EMBASE were searched via Ovid from inception until January 2019 
for meta-analyses involving patients with peripheral arterial disease on any 
antiplatelet therapy for any treatment outcome (Appendix A). The DARE, 
PROSPERO and Cochrane collaboration databases were searched separately. The 
related articles function on PubMed was used for every included meta-analysis, and 
reference lists of included meta-analyses were hand-searched. All publication types 
and languages were eligible. Two researchers (UC and CPT) independently 
screened titles and abstracts of articles for full text review. A third researcher (GKA) 
resolved differences. Full text articles were again double-reviewed. Cohort studies 
were excluded from analysis. 
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Eligibility criteria 
All meta-analyses involving subjects with PAD where any antiplatelet therapy was 
compared with another therapy were included. No restriction was made on the 
comparator group. Combination therapies were also included. Any outcome was 
allowed. Meta-analyses were included when they pooled any combination of relative 
risks, odds ratios, relative rates or hazard ratios comparing the same exposure with 
the same outcome. Studies which did not perform systematic review before meta-
analysis or did not perform meta-analysis were excluded.  
The primary objective was to provide an overview of all safety and efficacy 
outcomes included in at least one meta-analysis, for patients randomized to any 
antiplatelet regime.  
 
Data extraction 
CPT and CAW independently extracted data as per the protocol registered on 
PROSPERO 
(https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=84223). A 
standardised data collection proforma was used to improve reproducibility.  
After extraction, individual study data from each meta-analysis was re-analysed 
with data from multiple other analyses. When a meta-analysis had been updated 
(such as Cochrane reviews, which are regularly updated), the most up to date 
version was used. If a randomised trial had data discrepancies between different 
meta-analyses the original trial reference was examined and the data re-extracted. 
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Risk of bias (quality) assessment 
The AMSTAR measurement tool was used to assess the quality of included meta-
analyses.17,18 AMSTAR is a validated measurement tool to assess the 
methodological quality of systematic reviews, and ranges from 0 to 11 points.  
The GRADE classification was used to assess the quality of the evidence for 
each outcome.19 GRADE classifies the quality of evidence from included studies 
into: “high,” “moderate,” “low” and “very low” quality. This allows the overall strength 
of evidence for each individual meta-analysed outcome to be assessed.  
 
Strategy for data synthesis 
In order to give an overall picture of the effect of different antiplatelet strategies on a 
broad range of outcomes we grouped antiplatelet strategies into three main 
categories.   
1. Single antiplatelet therapy vs. placebo or no antiplatelet therapy 
2. Single antiplatelet therapy vs. dual antiplatelet therapy 
3. Single antiplatelet therapy vs. anticoagulation 
Single antiplatelet therapy was used as the baseline strategy as most guidelines 
currently recommend it for patients with PAD.  Meta-analysis was performed for 
these groupings, with pooled estimates calculated for overall summary effects and 
also subgroup analysis for specific antiplatelet agents.  It was not possible to 
compare by dose or duration of antiplatelet therapy because of a lack of data from 
included meta-analyses and heterogeneity between included trials.  
 
 
 
10 
 
Subgroup analysis 
Subgroup analysis was performed by antiplatelet agent/regime (described above) 
and by clinical subgroups. In order to provide more detailed information about the 
benefits and risks of a particular antiplatelet strategy for these subgroups, we 
performed the following subgroup analyses, where data was available: 
1. Asymptomatic patients 
2. Symptomatic patients 
3. Patients with intermittent claudication alone 
4. Patients undergoing endovascular intervention 
5. Patients undergoing open surgical intervention 
6. Patients undergoing any type of intervention 
It was not possible to examine patients with critical limb ischaemia separately as 
data was not available for this subgroup, though many trials included these patients. 
Because of the large number of analyses this produced, in order to report significant 
results clearly, each of the main results sections (above) were divided into: 
1. Safety and secondary prevention outcomes 
2. Limb outcomes 
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Statistical analysis 
Trial outcomes extracted from included meta-analyses were reanalysed using the 
DerSimonian and Laird random effects model.20 The Paule and Mandel method was 
used to calculate the between-study variance and its uncertainty for dichotomous 
data, and the restricted maximum likelihood estimator was used for continuous 
data,21,22 as these estimators have been shown in simulation studies to have reliable 
performance for these types of data.23 Higgins’ I2 statistic was used to quantify 
heterogeneity.24  Where more than 10 trials were available for analysis, Egger’s 
regression test was used to look for evidence of publication bias.25 All outcomes 
where an effect was significant at the 10% level were presented, as both risk ratios 
and also absolute event rates per 1000 patients.  Analysis was performed within the 
R statistical programming environment version 3.5.1, using the metafor package 
version 2.0-0 for meta-analysis.  Patency results are presented in the standard way, 
where events are losses of patency and thus more events signify a worse patency 
rate. 
 
Patient involvement 
The study was informed by feedback from qualitative patient interviews conducted as 
part of a randomised trial of patients undergoing major lower limb amputation for 
peripheral arterial disease,26 who were taking antiplatelet medication for a mixture of 
secondary and/or tertiary prevention. This preliminary data showed enthusiasm for 
trials of antiplatelet agents in this population.  
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Results 
The search yielded 1503 unique studies, from which 28 meta-analyses were 
included:9,27-53  21 including randomised trials alone,9,27-35,38-40,42-46,48,52,53 and 7 
including randomised trials and cohort studies (Figure 1, Appendix A).36,37,41,47,49-51 
These included data from 121 randomised trials involving 72,181 patients 
(Supplementary Table 1). The median number of included studies per meta-analysis 
was 15 (range 6 to 195). When meta-analyses with peripheral arterial patients only 
are considered the median was 14 with range 6-52. The median AMSTAR score was 
8 (range 3-11). The higher quality meta-analyses were all published by the Cochrane 
collaboration.28,29,32,35,48 We reanalysed 33 unique safety and efficacy outcomes from 
the 121 included studies.  
There were 41 discrete antiplatelet comparisons. Including subgroup analysis, 
we ran 1271 meta-analyses (referred to as ‘analyses’) in total. All analyses are 
shown in the supplementary resources. Trials investigating secondary prevention 
were generally larger when compared to trials of tertiary prevention after 
intervention. Trials examining antiplatelet strategy following peripheral endovascular 
intervention in particular were small and lower quality. 
There were five trials with discrepancies in patient and/or event numbers 
between meta-analyses, requiring data re-extraction.54-58 No included meta-analysis 
authors had to be contacted for data queries. 
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Antiplatelet monotherapy vs. placebo or no antiplatelet therapy 
Table 1 shows summary data for the most beneficial and harmful effects of 
antiplatelet monotherapy when compared to placebo or nothing, for all outcomes 
with an effect which is significant at the 10% level.  
 
Safety and secondary prevention outcomes  
Overall, there was high-quality evidence that antiplatelet monotherapy reduced non-
fatal strokes (3 fewer per 1000 patients, 95% CI 0–6; P=0.019), but at a cost of a 
significantly increased risk of major bleeding (4 more per 1000, 95% CI 1–8; 
P=0.009). 
In asymptomatic patients the only secondary prevention outcome where any 
benefit was found was for non-fatal stroke, where moderate quality evidence of a 
small absolute reduction was found (5 fewer per 1000 patients, 95% CI 0–8; 
P=0.055).   
In symptomatic patients there was again minimal evidence of benefit for 
antiplatelet monotherapy on secondary prevention outcomes, with a significant 
reduction in events at the 5% level only found for cardiovascular death. Even these 
benefits are offset by a significant increase in the risk of major bleeding; 8 
cardiovascular deaths were prevented per 1000 patients (95% CI 0–16; P=0.05), but 
there were 7 additional major bleeds (95% CI 3–14; P=0.002). There was no 
evidence of any secondary prevention benefit for aspirin or aspirin plus dipyridamole 
for any outcome other than non-fatal stroke. Many of the most beneficial effects for 
antiplatelet monotherapy were from trials using Ticlopidine as the antiplatelet agent 
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(Supplementary resources 1 and 2) , which has been withdrawn from market in 
many regions due to reports of thrombocytopenia, neutropenia and aplastic 
anaemia. 
 
Limb outcomes 
The most significant beneficial effects of monotherapy were generally limb-related 
and for patients undergoing intervention (Table 1): both vein and prosthetic bypass 
had primary patency benefits from antiplatelet therapy. 
 
Dual antiplatelet therapy vs. monotherapy 
Table 2 shows summary data for the most beneficial and harmful effects of dual 
antiplatelet therapy vs. antiplatelet monotherapy, for all outcomes with an effect 
which is significant at the 10% level. These were generally of lower GRADE quality 
than the outcomes of monotherapy vs. placebo or nothing, mainly as a result of 
imprecision.  
 
Safety and systemic outcomes 
Dual antiplatelet therapy resulted in significantly more major bleeding then 
monotherapy (Table 2). This is especially the case after intervention, where 37 more 
major bleeds per 1000 patients were caused by dual antiplatelet therapy (95% CI 8–
102; P=0.0048). 
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Limb outcomes 
Only two outcomes showed significant benefit at the 5% level with dual antiplatelet 
therapy, which were for prosthetic bypass patency at 24 months and amputation (low 
and moderate GRADE quality respectively, Table 2). There was very low quality 
evidence for dual antiplatelet therapy over monotherapy for endovascular 
intervention patency at 6 months from one trial (RR 4.00 95% CI 0.91–17.68, 
P=0.07).59  All meta-analyses are shown in Supplementary resources 1 and 3. 
 
Antiplatelet therapy vs. anticoagulation 
There were only eight trials examining this comparison (Table 3). Most of the 
analyses were informed by patients included in two trials.60,61 Major bleeding was not 
significantly different between the two groups and there were no significant 
differences in secondary prevention outcomes, although the trials were not powered 
to detect the latter.  
Patients undergoing vein bypass had better patency rates from anticoagulation 
than antiplatelet monotherapy (81 events per 1000 patients prevented at 24 months, 
95% CI 25–157; P=0.0024 GRADE quality moderate), whereas patients undergoing 
bypass using prosthetic grafts benefitted more from antiplatelet monotherapy than 
anticoagulation (81 events per 1000 patients prevented, 95% CI 25–128; P=0.0058 
GRADE quality moderate). All meta-analyses are shown in Supplementary 
resources 1 and 4. 
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Other antiplatelet comparisons 
Significant individual safety, secondary prevention and limb outcomes are described 
in detail in Appendix B.  Multiple other antiplatelet comparisons have been examined 
in randomised trials.  Details of all effect size estimates for different comparisons are 
given in Supplementary Resources 1–4.  Only four single trials found significant 
differences between trial treatments, and each trial had a different antiplatelet 
comparison.  These are shown in Supplementary Table 2. 
The CAPRIE trial recruited 11592 patients with symptomatic PAD, randomising 
them to either aspirin or clopidogrel.  They found significant benefit in terms of 
cumulative cardiovascular events and non-fatal myocardial infarction for patients 
treated with clopidogrel.54  The DAVID trial randomised 1209 patients with diabetes 
and PAD to aspirin or picotamide.56  They found significant benefit in terms of all-
cause mortality for patients treated with picotamide as well as fewer side effects for 
patients treated with picotamide.  In the STOP-IC trial 163 patients were randomised 
to either aspirin and cilostozol or aspirin and ticlopidine following endovascular 
intervention to femoropopliteal lesions.62  They found significantly fewer losses of 
primary patency at 12 and 24 months with aspirin and cilostazol. There was no 
significant difference in rates of major bleeding between trial treatments in any of 
these studies.  
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Discussion  
This analysis has shown that the benefits for antiplatelet therapy in PAD may 
historically have been overstated, and that the risks of harm have been understated. 
There is no secondary prevention benefit for patients with asymptomatic PAD taking 
antiplatelet monotherapy, but there is a significant increase in the risk of major 
bleeding. The improvement in secondary prevention of cardiovascular events in 
symptomatic patients with PAD taking antiplatelet monotherapy is modest at best: 
For every 8 cardiovascular deaths prevented in 1000 patients with symptomatic PAD 
there were 7 major bleeds. The risk of death from major bleeding is unclear, but no 
benefit is seen in terms of all-cause mortality, suggesting that any benefit in terms of 
reducing cardiovascular death is balanced by the associated harm.  
In the UK, NICE recommend clopidogrel monotherapy for all patients with 
PAD.3 This includes asymptomatic patients, who in this analysis derive no secondary 
prevention benefit but experience a risk of major bleeding when treated with 
antiplatelet agents. NICE relies heavily on data from the CAPRIE trial comparing 
clopidogrel with aspirin.54 The ESC guidelines also recommend antiplatelet 
monotherapy, more specifically for symptomatic patients.5 This contradicts the NICE 
and ACC/AHA guidelines. These guidelines cite subgroup analyses from large 
randomised trials, which are largely post-hoc analyses so need to be interpreted with 
caution. When combined in meta-analysis many of the significant results disappear. 
We would therefore suggest that even the benefit of antiplatelet monotherapy for 
symptomatic patients with PAD not undergoing intervention is unclear when 
balanced against the risk of major bleeding.   
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 Antiplatelet therapy appears more beneficial following intervention for PAD, 
with more events prevented than for secondary cardiovascular prevention. The 
quality of the evidence for outcomes following intervention was of lower GRADE 
quality than the secondary prevention evidence discussed above, with trials of 
hundreds of patients for intervention compared with thousands for secondary 
prevention. The most beneficial effects of antiplatelet monotherapy are for prosthetic 
bypass patency, where several hundred graft loss events per 1000 patients are 
prevented. However, prosthetic bypass is a poor second choice to autologous vein 
and its use should therefore be relatively limited.63 Anticoagulation is significantly 
more beneficial for vein bypasses than antiplatelet monotherapy, preventing 81 graft 
losses per 1000 patients at 2 years (Table 3, p<0.0001). It is possible that some of 
this benefit may be offset by higher bleeding risks with anticoagulation, but it is not 
possible to formally assess this as the two studies included in this analysis did not 
report this outcome for the subgroup of patients receiving a vein bypass rather than 
a prosthetic bypass.  
 Outcomes following endovascular intervention deserve special mention. The 
past decade has seen a huge expansion in peripheral endovascular interventions, 
with cases increasing threefold in England over the past decade from around 12,000 
cases in 2004-5 to over 33,000 in 2014-15 according to Hospital Episode Statistics. 
There is a trend towards dual antiplatelet prescribing after peripheral arterial 
intervention, the practice being extrapolated from coronary intervention data.64 
However there is currently no clear evidence of benefit for dual antiplatelets 
compared to monotherapy after peripheral intervention, but a clear risk of major 
bleeding: 37 more bleeds per 1000 patients (p=0.0048). As endovascular procedure 
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volume is predicted to continue increasing rapidly in line with the prevalence of 
diabetes,65,66 the benefits of dual antiplatelet therapy in patients undergoing 
endovascular therapy requires urgent evaluation.12  
There have been few recent trials of antiplatelet agents in PAD. The EUCLID 
trial comparing ticagrelor with clopidogrel showed no difference between the agents 
in the PAD (critical ischemia) subgroup.67 The COMPASS trial was a 3-arm trial 
comparing the combination of low-dose rivaroxaban and aspirin with rivaroxaban or 
aspirin alone for secondary prevention of cardiovascular events and found in favour 
of combination therapy.10 COMPASS showed that the combination of rivaroxaban 
and aspirin prevented 18 major adverse cardiovascular events per 1000 patients, 
while causing 12 additional major bleeds when compared to aspirin alone.10 The 
effect size is again relatively small for an expensive on-patent drug; by way of 
comparison, CAPRIE showed that clopidogrel  prevented 9 cumulative 
cardiovascular events over aspirin alone 20 years ago, with no significant difference 
in rates of major bleeding.54 Clopidogrel is now off patent and as such is significantly 
cheaper (Tariff price in the UK £1.40 per month) than the on-patent rivaroxaban 
(Tariff price £50.40 per month).68 
Umbrella review methodology has the benefit of giving a broad overview of a 
topic and the ability to compare the significance of event rates between a broad 
range of outcomes. However, because it relies on meta-analyses,  trials not yet 
included in meta-analysis will be missed. This is the case in this analysis for the new 
trials of the direct oral anticoagulants.10,69 We have, however, converted these trials’ 
results into event rates using the same statistical methods for the discussion. There 
are also newer antiplatelet agents which have some individual trials not included in 
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the analysis, the most prominent being the EUCLID trial comparing ticagrelor with 
clopidogrel. This, however, showed no difference between the two agents for any 
outcome.11,67,70,71  A further limitation of extracting data from meta-analyses is that it 
is difficult to correct for some deficiencies that are present in all available meta-
analyses.  A deficiency common to all of the included meta-analyses is that no 
information on the duration of follow-up is given for outcomes other than patency.  It 
is therefore unclear over what period of time we should expect to find the calculated 
event rates.  As the same studies generally presented both secondary prevention 
and safety outcomes, however, calculations which weigh the benefits of prevention 
against the harms of additional bleeding should remain valid as they are likely to 
have occurred over the same time period. 
 One strength of this umbrella review is that we have re-analysed the data. 
Standard umbrella review methodology extracts risk ratios intact and compares 
them. However when the literature is as extensive as it is in this field, meta-analyses 
included different studies and none could be viewed as definitive. Even the high 
quality meta-analyses included in this analysis had data discrepancies which were 
handled in this review by re-extracting primary trial data, and missing studies which 
were included by extracting the data from all analyses in this study.  
 There is a general lack of clinically meaningful data for outcome measures 
such as amputation-free survival and quality of life. This is a problem in the 
peripheral arterial literature in general, and newer lower limb trials are better 
designed to look at clinically meaningful, patient-centred outcomes.72 We were not 
able to separate data by interventions known to have different outcomes such as 
different types or techniques of endovascular intervention because the literature in 
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those areas was so poor. Some trial data will be confounded by patients having 
multiple types of arterial disease and therefore alternative indications for antiplatelet 
therapy, so the benefit may be greater than in patients with isolated PAD. This links 
in to the additional problem that some of the included trials were post-hoc subgroups 
of larger trials ostensibly examining outcomes for different types of arterial disease.  
We have presented appropriate clinical subgroups separately in order to provide 
treating clinicians with data which is as granular as possible, but the PAD 
populations recruited into large trials were a heterogenous group of patients with 
carotid disease, claudication and critical limb ischaemia, so there remain a number 
of areas (such as those undergoing lower limb endovascular therapy) where the 
available data is severely limited and further trials are needed. 
In addition to the heterogeneity in patient groups, the differences in antiplatelet 
agents and regimes/doses between trials made analysis challenging, although we 
tried to correct for this and explore the effect of different agents in subgroup analysis. 
No other high quality meta-analysis has attempted this previously, making this a 
more thorough exploration of the literature.  
Another limitation of our analysis is that the definition of major bleeding is 
heterogeneous between studies.  This is an established problem in cardiovascular 
trials and has resulted in several attempts to develop unifying definitions,73,74 with 
only limited success.  Reassuringly, despite these different definitions, the statistical 
heterogeneity on meta-analysis was not excessive for this outcome (Supplementary 
Resources 1—4). 
In summary, antiplatelet monotherapy should not be prescribed for patients 
with isolated asymptomatic peripheral arterial disease as it has no proven secondary 
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prevention benefit, and there may be a significant risk of major bleeding. 
Monotherapy only has modest secondary cardiovascular prevention benefits in 
patients with symptomatic peripheral arterial disease but also increases the risk of 
major bleeding; patients with no other indication for antiplatelet therapy should be 
counselled carefully for shared decision making. Antiplatelet monotherapy is 
effective in maintaining the patency of prosthetic lower limb bypass grafts while 
anticoagulation is more beneficial for vein grafts. There is a lack of evidence to guide 
antiplatelet prescribing after peripheral arterial endovascular intervention, which 
needs addressing urgently by adequately powered randomised trials. 
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Tables 
   Events / 1000     Egger’s 
P-value 
Strength of 
Evidence (GRADE) Outcome N Trials SAPT No APT RR 95% C.I. P-value I2 
Side-effects 3818 9 186 97 1.905 1.315—2.761 0.0007 50.1 NA Low 
OO 
Due to imprecision 
and inconsistency 
Major bleeding in 
symptomatic 
patients 
7648 37 16 9 1.730 1.220—2.453 0.0021 0 0.170 High 
 
Major bleeding 22996 46 15 11 1.349 1.079—1.686 0.0086 0 0.659 High 
 
Non-cardiovascular 
death after 
intervention 
3160 14 12 2 1.781 0.972—3.262 0.0618 0 0.767 Moderate 
O 
Due to imprecision 
Non-cardiovascular 
death after bypass 
2437 11 13 7 1.788 0.922—3.470 0.0857 0 0.668 Moderate 
O 
Due to imprecision 
 
Table 1a: Safety outcomes associated with antiplatelet monotherapy compared to placebo or nothing.  N: 
Number of patients; SAPT: Single Antiplatelet Therapy; APT: Antiplatelet therapy 
  
 
 
 
36 
   Events / 1000     
Egger’s 
P-value 
Strength of 
Evidence (GRADE) 
Outcome N Trials SAPT No APT RR 95% C.I. P-
value 
I2 
Non-fatal stroke 23559 46 14 17 0.787 0.644—
0.962 
0.0191 0 0.933 High 
 
Cardiovascular death in 
symptomatic patients 
10042 43 26 34 0.776 0.625—
0.964 
0.0220 0 0.272 High 
 
Cumulative 
cardiovascular events in 
symptomatic patients 
10151 45 57 66 0.869 0.755—
1.001 
0.0515 0 0.956 Moderate 
O 
Due to imprecision 
Cumulative 
cardiovascular events 
24428 55 54 60 0.908 0.823—
1.001 
0.0524 0 0.595 Moderate 
O 
Due to imprecision 
Cardiovascular death 
after bypass 
2437 11 27 41 0.665 0.439—
1.007 
0.0542 0 0.252 Moderate 
O 
Due to imprecision 
Non-fatal stroke in 
asymptomatic patients 
13542 4 14 19 0.773 0.595—
1.005 
0.0545 0 NA Moderate 
O 
Due to imprecision 
Cumulative 
cardiovascular events in 
claudicants 
6288 26 65 76 0.860 0.729—
1.015 
0.0736 0 0.433 Moderate 
O 
Due to imprecision 
Cardiovascular death in 
claudicants 
6288 26 27 34 0.785 0.600—
1.027 
0.0772 0 0.766 Moderate 
O 
Due to imprecision 
 
Table 1b: Secondary prevention outcomes associated with antiplatelet monotherapy compared to placebo 
or nothing.  N: Number of patients; SAPT: Single Antiplatelet Therapy; APT: Antiplatelet therapy 
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   Events / 1000     Egger’s 
P-value 
Strength of 
Evidence (GRADE) Outcome N Trials SAPT No APT RR 95% C.I. P-value I2 
Prosthetic 
bypass patency 
12 months 
222 4 194 538 0.361 0.238—0.549 <0.0001 0 NA Moderate 
O 
Due to imprecision 
Prosthetic 
bypass patency 
6 months 
222 4 162 443 0.365 0.225—0.593 <0.0001 0 NA Moderate 
O 
Due to imprecision 
Combined 
bypass patency 
6 months 
1107 6 119 242 0.493 0.324—0.750 0.0010 51.7 NA Low 
OO 
Due to imprecision 
and inconsistency 
Combined 
bypass patency 
24 months 
1195 7 200 353 0.566 0.387—0.827 0.0033 71.1 NA Low 
OO 
Due to imprecision 
and inconsistency 
Combined 
bypass patency 
12 months 
1195 7 184 329 0.560 0.380—0.826 0.0034 69.7 NA Low 
OO 
Due to imprecision 
and inconsistency 
Prosthetic 
bypass patency 
3 months 
222 4 104 255 0.408 0.216—0.773 0.0060 0 NA Moderate 
O 
Due to imprecision 
Prosthetic 
bypass patency 
1 month 
157 3 41 216 0.188 0.055—0.638 0.0074 0 NA Moderate 
O 
Due to imprecision 
Vein bypass 
patency 12 
months 
885 3 179 273 0.654 0.470—0.909 0.0115 25.7 NA Moderate 
O 
Due to imprecision 
Combined 
bypass patency 
3 months 
864 5 112 172 0.651 0.427—0.994 0.0469 19.7 NA Moderate 
O 
Due to imprecision 
Amputation in 
symptomatic 
patients 
1819 5 51 79 0.647 0.390—1.073 0.0918 41.8 NA Low 
OO 
Due to imprecision 
and inconsistency 
Ankle-brachial 
index 
911 5 - - 0.057 0.042—0.074 <0.0001 86.2 NA Moderate 
O 
Due to 
inconsistency 
Walking 
distance a 
2629 12 - - 44.65 25.44—63.87 <0.0001 81.8 6.8x10-5 Moderate 
O 
Due to 
inconsistency 
 
Table 1c: Limb outcomes associated with antiplatelet monotherapy compared to placebo or nothing.  N: 
Number of patients; SAPT: Single Antiplatelet Therapy; APT: Antiplatelet therapy 
a Walking distance is measured in metres, with positive numbers representing an improvement following 
antiplatelet monotherapy compared to placebo or nothing.  
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   Events per 1000     Strength of 
Evidence (GRADE) Outcome N Trials SAPT DAPT RR 95% C.I. P-Values I2 
Major bleeding after 
intervention 
931 2 21 58 0.368 0.183—0.737 0.0048 0 Moderate 
O 
Due to Imprecision 
Major bleeding after 
bypass surgery 
851 1 23 64 0.370 0.181— 0.754 0.0062 0 Low 
OO 
Due to Imprecision, 
risk of bias 
Major bleeding 20914 7 23 32 0.739 0.572— 0.954 0.0203 42.7 High 
 
Major bleeding in 
asymptomatic 
patients 
2219 2 64 85 0.751 0.559—1.009 0.0577 0 Moderate 
O 
Due to imprecision 
Cumulative 
cardiovascular 
events 
19517 9 49 43 1.124 0.989— 1.277 0.0727 0 Moderate 
O 
Due to imprecision 
Non-fatal Myocardial 
Infarction 
16195 6 23 19 1.205 0.977— 1.486 0.0818 0 Moderate 
O 
Due to imprecision 
Non-fatal Stroke in 
Claudicants 
2966 1 10 5 0.469 0.192— 1.146 0.0966 0 Low 
OO 
Due to imprecision, 
risk of bias 
Vein bypass patency 
at 24 months 
598 1 126 175 0.721 0.490—1.061 0.0971 0 Very Low 
OO 
Due to Imprecision, 
risk of bias 
Prosthetic bypass 
patency at 24 
months 
253 1 472 320 1.474 1.077—2.015 0.0152 0 Low 
OO 
Due to Imprecision, 
risk of bias 
Amputation 8115 3 15 11 1.453 1.000—2.112 0.0497 0 Moderate 
O 
Due to Imprecision 
Endovascular 
Intervention patency 
at 6 months 
80 1 200 50 4.000 0.905—17.681 0.0675 0 Very Low 
OOO 
Due to Imprecision, 
risk of bias 
Amputation in 
patients undergoing 
intervention 
891 2 103 70 1.468 0.952—2.264 0.0821 0 Low 
OO 
Due to Imprecision 
Amputation after 
bypass surgery 
851 1 106 73 1.448 0.935—2.243 0.0970 0 Very Low 
OOO 
Due to Imprecision, 
risk of bias 
 
Table 2: Safety, secondary prevention and limb outcomes associated with antiplatelet monotherapy 
compared to dual antiplatelet therapy.  N: Number of patients; SAPT: Single Antiplatelet Therapy; DAPT: 
Dual Antiplatelet therapy 
  
 
 
 
39 
   Events per 1000     Strength of 
Evidence (GRADE) Outcome N Trials SAPT Anti-Coag RR 95% C.I. P-value I2 
Side-effects 197 1 233 43 5.476 1.973—15.199 0.0011 0 Low 
OO 
Due to imprecision, 
risk of bias 
Vein bypass patency 
24 months 
1618 2 224 143 1.567 1.172—2.093 0.0024 0 Moderate 
O 
Due to imprecision 
Vein bypass patency 
12 months 
1630 2 177 123 1.436 1.134—1.820 0.0027 0 Moderate 
O 
Due to imprecision 
Vein bypass patency 6 
months 
1632 2 144 111 1.306 1.010—1.688 0.0416 0 Moderate 
O 
Due to imprecision 
Prosthetic bypass 
patency 24 months 
1104 1 329 410 0.804 0.688—0.939 0.0058 0 Moderate 
O 
Due to risk of bias 
Prosthetic bypass 
patency 6 months 
1104 1 157 214 0.732 0.569—0.940 0.0146 0 Low 
OO 
Due to imprecision, 
risk of bias 
Endovascular 
intervention patency 12 
months 
589 4 231 312 0.741 0.569—0.965 0.0261 0 Moderate 
O 
Due to imprecision 
Prosthetic bypass 
patency 12 months 
1104 1 244 301 0.811 0.668—0.984 0.0340 0 Low 
OO 
Due to imprecision, 
risk of bias 
Cumulative 
cardiovascular events 
after bypass surgery 
2690 1 66 48 1.378 1.009—1.883 0.0440 0 Low 
OO 
Due to imprecision, 
risk of bias 
 
Table 3: Safety, secondary prevention and limb outcomes from antiplatelet monotherapy compared to 
anticoagulation.  N: Number of patients; SAPT: Single Antiplatelet Therapy; Anti-Coag: Anti-coagulation. 
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Figure caption 
Figure 1. Flowchart of selection of studies for inclusion in umbrella review on 
antiplatelet therapy and peripheral arterial disease. 
